Modality
ERT
MOA
PRMT5i
Target
BET
Pathway
Neuroinflam
MS
Development Pipeline
Preclinical
~Jul 2020
→ ~Oct 2021
Phase 1
Jan 2022
→ Apr 2029
Phase 1Current
NCT05000748
805 pts·MS
2022-01→2029-04·Not yet recruiting
805 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-04-083.0y awayPh2 Data· MS
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P1/2
Not yet…
Catalysts
Ph2 Data
2029-04-08 · 3.0y away
MS
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05000748 | Phase 1/2 | MS | Not yet recr... | 805 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-1969 | Roche | Approved | BET | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| NVS-5439 | Novartis | Preclinical | BET | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa |